Identification

Name
Pravastatin
Accession Number
DB00175  (APRD00328)
Type
Small Molecule
Groups
Approved
Description

Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered. It is a ring-opened dihydroxyacid with a 6’-hydroxyl group that does not require in vivo activation. Pravastatin is one of the lower potency statins; however, its increased hydrophilicity is thought to confer advantages such as minimal penetration through lipophilic membranes of peripheral cells, increased selectivity for hepatic tissues, and a reduction in side effects compared with lovastatin and simvastatin.

Structure
Thumb
Synonyms
  • (+)-(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid
  • Pravastatin acid
  • Pravastatina
  • Pravastatine
  • Pravastatinum
Product Ingredients
IngredientUNIICASInChI Key
Pravastatin sodium3M8608UQ6181131-70-6VWBQYTRBTXKKOG-IYNICTALSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act PravastatinTablet10 mgOralActavis Pharma Company2003-12-09Not applicableCanada
Act PravastatinTablet40 mgOralActavis Pharma Company2003-12-09Not applicableCanada
Act PravastatinTablet20 mgOralActavis Pharma Company2003-12-09Not applicableCanada
Bio PravastatinTablet10 mgOralBioenhance Medicines Inc.2001-07-122003-02-27Canada
Bio PravastatinTablet40 mgOralBioenhance Medicines Inc.2001-07-122003-02-27Canada
Bio PravastatinTablet20 mgOralBioenhance Medicines Inc.2001-07-122003-02-27Canada
M-pravastatinTablet20 mgOralMantra Pharma IncNot applicableNot applicableCanada
M-pravastatinTablet10 mgOralMantra Pharma IncNot applicableNot applicableCanada
M-pravastatinTablet40 mgOralMantra Pharma IncNot applicableNot applicableCanada
PravacholTablet20 mg/1OralE.R. Squibb & Sons, L.L.C.2009-06-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ach-pravastatinTablet20 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-pravastatinTablet10 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-pravastatinTablet40 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Apo-pravastatinTablet10 mgOralApotex Corporation2001-02-27Not applicableCanada
Apo-pravastatinTablet40 mgOralApotex Corporation2001-02-27Not applicableCanada
Apo-pravastatinTablet20 mgOralApotex Corporation2001-02-27Not applicableCanada
Auro-pravastatinTablet10 mgOralAuro Pharma IncNot applicableNot applicableCanada
Auro-pravastatinTablet40 mgOralAuro Pharma IncNot applicableNot applicableCanada
Auro-pravastatinTablet20 mgOralAuro Pharma IncNot applicableNot applicableCanada
Ava-pravastatinTablet20 mgOralAvanstra Inc2011-10-112011-12-12Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Pal-pravastatin-asaPravastatin sodium (10 mg) + Acetylsalicylic acid (81 mg)Kit; Tablet; Tablet, delayed releaseOralPaladin Labs Inc2006-01-132015-07-31Canada
Pal-pravastatin-asaPravastatin sodium (40 mg) + Acetylsalicylic acid (81 mg)Kit; Tablet; Tablet, delayed releaseOralPaladin Labs Inc2006-01-132015-07-31Canada
Pal-pravastatin-asaPravastatin sodium (20 mg) + Acetylsalicylic acid (81 mg)Kit; Tablet; Tablet, delayed releaseOralPaladin Labs Inc2006-01-132015-07-31Canada
Pravigard PacPravastatin sodium (40 mg/1) + Acetylsalicylic acid (81 mg/1)KitE.R. Squibb & Sons, L.L.C.2005-01-012006-12-31Us
Pravigard PacPravastatin sodium + Acetylsalicylic acidTabletBristol-Myers Squibb Company2006-10-122006-10-12Us
Pravigard PacPravastatin sodium + Acetylsalicylic acidKitBristol-Myers Squibb Company2006-10-122006-10-12Us
Pravigard PacPravastatin sodium + Acetylsalicylic acidTabletBristol-Myers Squibb Company2006-10-122006-10-12Us
Pravigard PacPravastatin sodium (40 mg/1) + Acetylsalicylic acid (325 mg/1)KitE.R. Squibb & Sons, L.L.C.2006-01-012007-04-30Us
Pravigard PacPravastatin sodium + Acetylsalicylic acidTabletBristol-Myers Squibb Company2006-10-122006-10-12Us
International/Other Brands
Elisor / Lipostat / Mevalotin / Pravaselect / Selipran
Categories
UNII
KXO2KT9N0G
CAS number
81093-37-0
Weight
Average: 424.5277
Monoisotopic: 424.246103506
Chemical Formula
C23H36O7
InChI Key
TUZYXOIXSAXUGO-PZAWKZKUSA-N
InChI
InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1
IUPAC Name
(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
SMILES
[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC

Pharmacology

Indication

For the treatment of hypercholesterolemia and to reduce the risk of cardiovascular disease.

Associated Conditions
Pharmacodynamics

The primary cause of cardiovascular (CV) disease is atherosclerotic plaque formation and sustained elevation of cholesterol in the blood increases the risk of CV disease. Pravastatin lowers hepatic production of cholesterol by competitively inhibiting HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step in the cholesterol biosynthesis pathway via the mevalonic acid pathway. Decreased hepatic cholesterol levels causes increased uptake of low density lipoprotein (LDL) cholesterol and reduces cholesterol levels in the circulation. Pravastatin also inhibits hepatic synthesis if VLDL. At therapeutic doses, pravastatin lowers LDL cholesterol by 20-30%, increase high density lipoprotein (HDL) cholesterol by 3-10%, and decrease plasma triglycerides by 19-34%. HDL cholesterol is thought to confer protective effects against CV disease, whereas high LDL and triglyceride levels are associated with higher risk of disease.

Mechanism of action

Pravastatin is structurally similar to the HMG, a substituent of the endogenous substrate of HMG-CoA reductase. Unlike its parent compound, mevastatin, and statins such as lovastatin and simvastatin, pravastatin does not need to be activated in vivo. Its hydrolyzed lactone ring mimics the tetrahedral intermediate produced by the reductase allowing the agent to bind with a much greater affinity than its natural substrate. The bicyclic portion of pravastatin binds to the coenzyme A portion of the active site. Pravastatin sodium produces its lipid-lowering effect in two ways. First, as a consequence of its reversible inhibition of HMG-CoA reductase activity, it effects modest reductions in intracellular pools of cholesterol. This results in an increase in the number of LDL-receptors on cell surfaces and enhanced receptor-mediated catabolism and clearance of circulating LDL. Second, pravastatin inhibits LDL production by inhibiting hepatic synthesis of VLDL, the LDL precursor.

TargetActionsOrganism
A3-hydroxy-3-methylglutaryl-coenzyme A reductase
inhibitor
Human
Absorption

Pravastatin is rapidly absorbed with peak plasma levels of the parent compound achieved 1 to 1.5 hours after administration. The average oral absorption of pravastatin is 34% and absolute bioavailability is 17%. These values however, are variable. Food decreases the systemic bioavailability but the lipid-lowering effect is not impacted. When 20 mg of pravastatin is given orally, the pharmacokinetic parameters are as follows: Cmax = 23.3-26.3 ng/mL; AUC = 54.7 to 62.2 ng•hr/mL.

Volume of distribution
Not Available
Protein binding

50% bound to human plasma proteins.

Metabolism

Hepatic, there is a small amount of metabolism by P450 enzymes, but this effect is so minimal that inhibitory pharmacokinetic drug interactions have no real effect on its overall activity and elimination. An in vitro study which found moderate affinity for P450 2C9 (major), 2D6 and 3A4. Furthermore, the major degradation product is the 3α-hydroxy isomeric metabolite, which has one-tenth to one-fortieth the HMG-CoA reductase inhibitory activity of the parent compound.

Route of elimination

Approximately 20% of a radiolabeled oral dose is excreted in urine and 70% in the feces. After intravenous administration, 47% of total body clearance was via renal excretion, while 53% was eliminated by non-renal routes.

Half life

1.8h [1]

Clearance
Not Available
Toxicity

Side effects include diarrhea, nausea, constipation, gas abdominal pain, myopathy, myositis, rhabdomyolysis, and hepatotoxicity. LD50= 12,000 mg/kg (orally in rat)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Pravastatin Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Kinesin-like protein KIF6---(C;C) / (C;T)C AlleleEffect Directly StudiedPatients with this genotype have a greater reduction in risk of a major cardiovascular event with high dose pravastatin.Details
3-hydroxy-3-methylglutaryl-coenzyme A reductase---(A;T)T AlleleEffect Directly StudiedPatients with this genotype have a lesser reduction in LDL cholesterol with pravastatin.Details

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of bleeding can be increased when Pravastatin is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Pravastatin is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Pravastatin is combined with 4-hydroxycoumarin.
AbemaciclibThe serum concentration of Pravastatin can be increased when it is combined with Abemaciclib.
AcalabrutinibThe metabolism of Pravastatin can be decreased when combined with Acalabrutinib.
AcenocoumarolThe risk or severity of bleeding can be increased when Pravastatin is combined with Acenocoumarol.
AcetaminophenThe serum concentration of Pravastatin can be increased when it is combined with Acetaminophen.
AcetylcysteineThe excretion of Pravastatin can be decreased when combined with Acetylcysteine.
AcipimoxAcipimox may increase the myopathic rhabdomyolysis activities of Pravastatin.
AcyclovirThe excretion of Acyclovir can be decreased when combined with Pravastatin.
Food Interactions
  • Avoid alcohol.
  • Avoid drastic changes in dietary habit.
  • Take without regard to meals.

References

Synthesis Reference

Kae Jong Chung, Joo Kyung Lee, Joo Woong Park, Dong Jin Seo, Sang Choon Lee, "Method for producing pravastatin precursor, ML-236B." U.S. Patent US6204032, issued October, 1976.

US6204032
General References
  1. Pan HY: Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. Eur J Clin Pharmacol. 1991;40 Suppl 1:S15-8. [PubMed:1904355]
  2. Hedman M, Neuvonen PJ, Neuvonen M, Antikainen M: Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia. Clin Pharmacol Ther. 2003 Aug;74(2):178-85. doi: 10.1016/S0009-9236(03)00153-X. [PubMed:12891228]
External Links
Human Metabolome Database
HMDB0005022
KEGG Drug
D08410
KEGG Compound
C01844
PubChem Compound
54687
PubChem Substance
46504851
ChemSpider
49398
BindingDB
20688
ChEBI
63618
ChEMBL
CHEMBL1144
Therapeutic Targets Database
DAP000550
PharmGKB
PA451089
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Pravastatin
ATC Codes
C10AA03 — PravastatinC10BX02 — Pravastatin and acetylsalicylic acidC10BA03 — Pravastatin and fenofibrate
AHFS Codes
  • 24:06.08 — Hmg-coa Reductase Inhibitors
FDA label
Download (251 KB)
MSDS
Download (44 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedPreventionVentilator-associated Bacterial Pneumonia1
1Active Not RecruitingTreatmentLeukemias1
1CompletedNot AvailableHealthy Volunteers4
1CompletedBasic ScienceCancer, Breast1
1CompletedBasic ScienceDrug Biotransformation / Membrane Transport1
1CompletedBasic ScienceDrug Drug Interaction (DDI)1
1CompletedBasic ScienceGenotype-related Drug Metabolism1
1CompletedBasic ScienceHealthy Volunteers3
1CompletedBasic ScienceRheumatoid Arthritis1
1CompletedOtherHealthy Volunteers / Rheumatoid Arthritis1
1CompletedPreventionGlomerulonephritis minimal lesion / Hyperlipidemias1
1CompletedTreatmentAcute Kidney Injury (AKI)1
1CompletedTreatmentDrug Distribution1
1CompletedTreatmentHIV Seronegativity / Human Immunodeficiency Virus (HIV) Infections / Lipodystrophies1
1CompletedTreatmentHealthy Volunteers4
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections3
1CompletedTreatmentLeukemias1
1CompletedTreatmentTherapeutic Equivalency2
1RecruitingNot AvailableHealthy Volunteers1
1RecruitingPreventionPreeclampsia1
1RecruitingTreatmentDyslipidemias / Peripheral Artery Disease (PAD)1
1, 2TerminatedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia1
1, 2TerminatedTreatmentAlbinism, Oculocutaneous / Hermansky-Pudlak Syndrome (HPS) / Metabolic Diseases / Platelet Storage Pool Deficiency / Pulmonary Fibrosis1
2Active Not RecruitingTreatmentCHILD B / Hepatocellular,Carcinoma1
2Active Not RecruitingTreatmentLeukemias1
2CompletedTreatmentCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Ischemia1
2CompletedTreatmentDiabetes Mellitus (DM) / High Cholesterol / Metabolic Syndromes1
2CompletedTreatmentDyslipidemias1
2CompletedTreatmentHigh Cholesterol / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentHigh Cholesterol / Statin-Associated Myopathy1
2CompletedTreatmentHutchinson-Gilford Syndrome / Progeria1
2CompletedTreatmentLupus / Systemic Lupus Erythematosus (SLE)1
2CompletedTreatmentType II Hyperlipidaemia1
2Enrolling by InvitationTreatmentProgeria1
2Not Yet RecruitingTreatmentCoronary Heart Disease (CHD) / Human Immunodeficiency Virus (HIV) Infections1
2Not Yet RecruitingTreatmentTuberculosis Infection1
2RecruitingPreventionProphylaxis of preeclampsia1
2RecruitingTreatmentFibrosis1
2Unknown StatusTreatmentAdvanced Hepatocarcinoma1
2WithdrawnTreatmentInfection, Human Immunodeficiency Virus I1
2WithdrawnTreatmentMucocutaneous Lymph Node Syndrome1
3CompletedBasic ScienceHigh Cholesterol / Hyperlipoproteinemias1
3CompletedPreventionCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Heart Diseases / Heart Failure, Unspecified / High Blood Pressure (Hypertension) / High Cholesterol / Myocardial Infarction / Myocardial Ischemia1
3CompletedPreventionCardiovascular Disease (CVD) / Kidney Diseases / Microalbuminuria1
3CompletedPreventionStroke, Ischemic1
3CompletedTreatmentArterial Occlusive Diseases / Cardiovascular Disease (CVD) / Diabetes Mellitus (DM) / Heart Diseases / Vascular Diseases1
3CompletedTreatmentAtherosclerosis / Cardiovascular Disease (CVD)1
3CompletedTreatmentAutosomal Dominant Polycystic Kidney Disease (ADPKD)1
3CompletedTreatmentChild-Pugh A Hepatocellular Carcinoma1
3CompletedTreatmentChronic Allograft Nephropathy (CAN) / End-Stage Renal Disease (ESRD)1
3CompletedTreatmentCombined Hyperlipidemia1
3CompletedTreatmentHigh Cholesterol2
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lipodystrophies1
3CompletedTreatmentHypercholesterolemia or Combined Dyslipidemia1
3CompletedTreatmentHyperlipidemias1
3CompletedTreatmentHyperlipoproteinemia Type III1
3CompletedTreatmentLiver Cancer1
3CompletedTreatmentLung Cancers1
3CompletedTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
3RecruitingTreatmentHigh Cholesterol2
3TerminatedTreatmentHigh Blood Pressure (Hypertension)1
3TerminatedTreatmentHigh Cholesterol1
4CompletedPreventionActue Coronary Syndromes1
4CompletedPreventionAging / Alzheimer's Disease (AD)1
4CompletedPreventionCardiovascular Disease (CVD)1
4CompletedPreventionHyperlipidemias1
4CompletedTreatmentAcute Coronary Syndromes (ACS)1
4CompletedTreatmentCardiovascular Disease (CVD) / Glucose Metabolism / Human Immunodeficiency Virus (HIV) Infections / Lipodystrophies / Metabolic Abnormality / Metabolism, Lipids1
4CompletedTreatmentChronic Heart Failure (CHF)1
4CompletedTreatmentChronic Stable Angina Pectoris / Non ST Segment Elevation Myocardial Infarction (NSTEMI) / Unstable Angina Pectoris1
4CompletedTreatmentCoronary Arteriosclerosis1
4CompletedTreatmentCoronary Heart Disease (CHD) / High Cholesterol1
4CompletedTreatmentDiabetes Mellitus (DM) / Prediabetic State1
4CompletedTreatmentDyslipidemias2
4CompletedTreatmentHigh Cholesterol2
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Hyperlipidemias2
4CompletedTreatmentHypertriglycemia / Type 2 Diabetes Mellitus1
4CompletedTreatmentMulti-vessel Diseases, Angina1
4CompletedTreatmentMixed hypercholesterolemia / Primary Dyslipidemia1
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorders1
4CompletedTreatmentType IIa and IIb Hypercholesterolaemia1
4RecruitingHealth Services ResearchDiabetes Mellitus (DM)1
4RecruitingPreventionHigh Blood Pressure (Hypertension) / Strokes / Transient Ischaemic Attack (TIA)1
4RecruitingTreatmentAutosomal Dominant Polycystic Kidney Disease (ADPKD)1
4RecruitingTreatmentChronic Kidney Disease (CKD)1
4RecruitingTreatmentCoronary Artery Disease1
4TerminatedNot AvailableStatin Adverse Reaction / Statin-Associated Myopathy1
4TerminatedTreatmentChronic Kidney Disease (CKD)1
4TerminatedTreatmentHeart Failure, Unspecified1
4Unknown StatusPreventionAcute Myocardial Infarction (AMI)1
4Unknown StatusTreatmentCoronary Heart Disease (CHD) / High Cholesterol1
4Unknown StatusTreatmentDrug-eluting Stent (DES)1
4Unknown StatusTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
4Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections / Hyperlipidemias1
Not AvailableCompletedNot AvailableCardiovascular Disease (CVD) / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableHigh Cholesterol3
Not AvailableCompletedNot AvailablePediatrics Patients on Dialysis1
Not AvailableCompletedNot AvailablePostpartum Depression1
Not AvailableCompletedPreventionCardiovascular Disease Risk / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Refractory Anemia With Excess Blasts / Untreated Adult Acute Myeloid Leukemia1
Not AvailableCompletedTreatmentCoronary Artery Disease1
Not AvailableNot Yet RecruitingTreatmentEndometriosis1
Not AvailableRecruitingTreatmentCoronary Artery Occlusive Disease1
Not AvailableTerminatedPreventionHigh Blood Pressure (Hypertension) / High Cholesterol / Type 2 Diabetes Mellitus1
Not AvailableTerminatedTreatmentMetabolic Syndromes1
Not AvailableUnknown StatusScreeningDyslipidemias1
Not AvailableUnknown StatusTreatmentCrohn's Disease (CD)1
Not AvailableUnknown StatusTreatmentHeart Diseases1
Not AvailableWithdrawnTreatmentEndometriosis1

Pharmacoeconomics

Manufacturers
  • Bristol myers squibb
  • Apotex corp
  • Dr reddys laboratories inc
  • Glenmark generics ltd
  • Lek pharmaceuticals dd
  • Lupin pharmaceuticals inc
  • Matrix laboratories ltd
  • Mylan pharmaceuticals inc
  • Pliva hrvatska doo
  • Ranbaxy laboratories ltd
  • Teva pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Amerisource Health Services Corp.
  • Apotex Inc.
  • A-S Medication Solutions LLC
  • Bristol-Myers Squibb Co.
  • Bryant Ranch Prepack
  • Cadila Healthcare Ltd.
  • Cardinal Health
  • Cobalt Pharmaceuticals Inc.
  • Comprehensive Consultant Services Inc.
  • Dept Health Central Pharmacy
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Doctor Reddys Laboratories Ltd.
  • E.R. Squibb and Sons LLC
  • Glenmark Generics Ltd.
  • International Laboratories Inc.
  • Kaiser Foundation Hospital
  • Lek Pharmaceuticals Inc.
  • Lupin Pharmaceuticals Inc.
  • Major Pharmaceuticals
  • Medvantx Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Neuman Distributors Inc.
  • Ohm Laboratories Inc.
  • Palmetto Pharmaceuticals Inc.
  • Par Pharmaceuticals
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Physicians Total Care Inc.
  • Pliva Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Resource Optimization and Innovation LLC
  • Sandoz
  • Southwood Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Vangard Labs Inc.
  • Zydus Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral10 mg
Kit; tablet; tablet, delayed releaseOral
TabletOral10 mg/1
TabletOral80 mg
TabletOral20 mg
TabletOral40 mg
TabletOral20 mg/1
TabletOral40 mg/1
TabletOral80 mg/1
Kit
Tablet
Prices
Unit descriptionCostUnit
Pravachol 40 mg tablet6.53USD tablet
Pravachol 80 mg tablet6.53USD tablet
Pravastatin sodium 40 mg tablet4.89USD tablet
Pravastatin sodium 80 mg tablet4.89USD tablet
Pravachol 20 mg tablet4.39USD tablet
Pravachol 10 mg tablet4.38USD tablet
Pravastatin sodium 20 mg tablet3.33USD tablet
Pravastatin sodium 10 mg tablet3.28USD tablet
Apo-Pravastatin 40 mg Tablet1.42USD tablet
Co Pravastatin 40 mg Tablet1.42USD tablet
Jamp-Pravastatin 40 mg Tablet1.42USD tablet
Mint-Pravastatin 40 mg Tablet1.42USD tablet
Mylan-Pravastatin 40 mg Tablet1.42USD tablet
Novo-Pravastatin 40 mg Tablet1.42USD tablet
Pms-Pravastatin 40 mg Tablet1.42USD tablet
Pravachol 40 mg Tablet1.42USD tablet
Ran-Pravastatin 40 mg Tablet1.42USD tablet
Ratio-Pravastatin 40 mg Tablet1.42USD tablet
Sandoz Pravastatin 40 mg Tablet1.42USD tablet
Apo-Pravastatin 20 mg Tablet1.18USD tablet
Co Pravastatin 20 mg Tablet1.18USD tablet
Jamp-Pravastatin 20 mg Tablet1.18USD tablet
Mint-Pravastatin 20 mg Tablet1.18USD tablet
Mylan-Pravastatin 20 mg Tablet1.18USD tablet
Novo-Pravastatin 20 mg Tablet1.18USD tablet
Pms-Pravastatin 20 mg Tablet1.18USD tablet
Pravachol 20 mg Tablet1.18USD tablet
Ran-Pravastatin 20 mg Tablet1.18USD tablet
Ratio-Pravastatin 20 mg Tablet1.18USD tablet
Sandoz Pravastatin 20 mg Tablet1.18USD tablet
Apo-Pravastatin 10 mg Tablet1.0USD tablet
Co Pravastatin 10 mg Tablet1.0USD tablet
Jamp-Pravastatin 10 mg Tablet1.0USD tablet
Mint-Pravastatin 10 mg Tablet1.0USD tablet
Mylan-Pravastatin 10 mg Tablet1.0USD tablet
Novo-Pravastatin 10 mg Tablet1.0USD tablet
Pms-Pravastatin 10 mg Tablet1.0USD tablet
Pravachol 10 mg Tablet1.0USD tablet
Ran-Pravastatin 10 mg Tablet1.0USD tablet
Ratio-Pravastatin 10 mg Tablet1.0USD tablet
Sandoz Pravastatin 10 mg Tablet1.0USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5622985No1994-10-222014-10-22Us
CA1323836No1993-11-022010-11-02Canada

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)171.2 - 173°CMSDS
water solubilitySoluble FDA label
logP0.59 FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.242 mg/mLALOGPS
logP2.23ALOGPS
logP1.65ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)4.21ChemAxon
pKa (Strongest Basic)-2.7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area124.29 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity113.6 m3·mol-1ChemAxon
Polarizability46.56 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0uk9-0009000000-967b377abafe64b73071
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0002900000-bd7fd66d793ae64426ff
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-4809000000-0ed5a8797dfc49ecf5af
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-2900000000-91b125182ce5d90f16ab
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-1900000000-e8fc6384260de93c5aa8
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-1900000000-11e99968bc0ba393b6f9
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-4900000000-0e4265e6dc1468c1471d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0002900000-8795ee00dded0ef8be48
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-3709000000-aa45be15af0471c0a46e
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-2900000000-5617409991f5c58e5130
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-2900000000-2bf5c13979a639625d1c
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-2900000000-9a233e521607e82ab7a0
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-0900000000-2083dfbb67bf2b03ccf9
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0uk9-0009000000-4b2c09a295ba7f3ce41b
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-0607900000-e57e263ad3f74bfda195

Taxonomy

Description
This compound belongs to the class of organic compounds known as medium-chain hydroxy acids and derivatives. These are hydroxy acids with a 6 to 12 carbon atoms long side chain.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Hydroxy acids and derivatives
Sub Class
Medium-chain hydroxy acids and derivatives
Direct Parent
Medium-chain hydroxy acids and derivatives
Alternative Parents
Fatty alcohols / Medium-chain fatty acids / Hydroxy fatty acids / Fatty acid esters / Branched fatty acids / Beta hydroxy acids and derivatives / Dicarboxylic acids and derivatives / Secondary alcohols / Carboxylic acid esters / Carboxylic acids
show 3 more
Substituents
Fatty alcohol / Medium-chain hydroxy acid / Medium-chain fatty acid / Beta-hydroxy acid / Branched fatty acid / Hydroxy fatty acid / Fatty acid ester / Fatty acyl / Dicarboxylic acid or derivatives / Secondary alcohol
show 10 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
statin (semi-synthetic), carboxylic ester, secondary alcohol, 3-hydroxy carboxylic acid, hydroxy monocarboxylic acid, carbobicyclic compound (CHEBI:63618)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Nadph binding
Specific Function
Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis as well as in the biosynthesis of nonsterol isoprenoids that are essential for normal cell function including...
Gene Name
HMGCR
Uniprot ID
P04035
Uniprot Name
3-hydroxy-3-methylglutaryl-coenzyme A reductase
Molecular Weight
97475.155 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Backman JT, Filppula AM, Niemi M, Neuvonen PJ: Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacol Rev. 2016 Jan;68(1):168-241. doi: 10.1124/pr.115.011411. [PubMed:26721703]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46. Epub 2004 Dec 22. [PubMed:15616150]
  2. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. [PubMed:10601278]
  3. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800]
  4. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005 Jul;15(7):513-22. [PubMed:15970799]
  5. Sharma P, Holmes VE, Elsby R, Lambert C, Surry D: Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions. Xenobiotica. 2010 Jan;40(1):24-37. doi: 10.3109/00498250903351013. [PubMed:19919292]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name
SLCO2B1
Uniprot ID
O94956
Uniprot Name
Solute carrier organic anion transporter family member 2B1
Molecular Weight
76709.98 Da
References
  1. Mougey EB, Feng H, Castro M, Irvin CG, Lima JJ: Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics. 2009 Feb;19(2):129-38. doi: 10.1097/FPC.0b013e32831bd98c. [PubMed:19151602]
  2. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther. 2003 Aug;306(2):703-8. Epub 2003 Apr 30. [PubMed:12724351]
  3. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45. Epub 2003 Nov 10. [PubMed:14610227]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46. Epub 2004 Dec 22. [PubMed:15616150]
  2. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. [PubMed:10601278]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359]
  2. Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, Endou H, Sugiyama Y: Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. J Pharmacol Exp Ther. 2002 Mar;300(3):746-53. [PubMed:11861777]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359]
  2. Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, Terasaki T: Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J Pharmacol Exp Ther. 2004 Jun;309(3):1273-81. Epub 2004 Feb 4. [PubMed:14762099]
  3. Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, Endou H, Sugiyama Y: Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. J Pharmacol Exp Ther. 2002 Mar;300(3):746-53. [PubMed:11861777]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46. Epub 2004 Dec 22. [PubMed:15616150]
  2. Yamazaki M, Akiyama S, Ni'inuma K, Nishigaki R, Sugiyama Y: Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab Dispos. 1997 Oct;25(10):1123-9. [PubMed:9321514]
  3. Sasaki M, Suzuki H, Ito K, Abe T, Sugiyama Y: Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). J Biol Chem. 2002 Feb 22;277(8):6497-503. Epub 2001 Dec 17. [PubMed:11748225]
  4. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y: ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003 Jun 20;278(25):22644-9. Epub 2003 Apr 7. [PubMed:12682043]
  2. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
Gene Name
SLC22A7
Uniprot ID
Q9Y694
Uniprot Name
Solute carrier family 22 member 7
Molecular Weight
60025.025 Da
References
  1. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Symporter activity
Specific Function
Proton-coupled monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucin...
Gene Name
SLC16A1
Uniprot ID
P53985
Uniprot Name
Monocarboxylate transporter 1
Molecular Weight
53943.685 Da
References
  1. Tamai I, Takanaga H, Maeda H, Ogihara T, Yoneda M, Tsuji A: Proton-cotransport of pravastatin across intestinal brush-border membrane. Pharm Res. 1995 Nov;12(11):1727-32. [PubMed:8592677]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Morisawa Y, Takikawa H: Effect of bile acids on the biliary excretion of pravastatin in rats. Hepatol Res. 2009 Jun;39(6):595-600. doi: 10.1111/j.1872-034X.2009.00493.x. Epub 2009 Feb 24. [PubMed:19260999]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
References
  1. Link [Link]

Drug created on June 13, 2005 07:24 / Updated on November 13, 2018 07:44